To minimize any sex and APOE-ε4-related variability, we utilized well-characterized iPSCs from 2 AD and 2 control female participants with APOE-ε4/ε4 genotypes for pericyte differentiation79 followed by treatments to activate or inhibit VEGFA signaling80–83. This evidence concerns the gene VEGFA and Alzheimer disease.